Related Experiment Video

Updated: Dec 23, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.1K

Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis

Sima Lev1

  • 1Molecular Cell Biology Department, Weizmann Institute of Science, Rehovot, Israel.

Biochemical Society Transactions
|April 21, 2020
PubMed

Insights

Targeted therapies are vital for hormone-positive and HER2-positive breast cancer. This review focuses on identifying new therapeutic targets and combination strategies for triple-negative breast cancer (TNBC) to overcome treatment resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Estrogen receptor (ER) and HER2-targeted therapies are mainstays in breast cancer treatment.
  • Triple-negative breast cancer (TNBC) lacks targeted therapy options, necessitating urgent research.
  • Understanding resistance mechanisms is crucial for developing effective treatments.

Purpose of the Study:

  • To review general strategies for inhibiting tumor growth via targeted therapies.
  • To focus on emerging therapeutic targets for TNBC.
  • To discuss combination therapies, particularly targeting the epidermal growth factor receptor (EGFR), and resistance mechanisms.

Main Methods:

  • Literature review of targeted therapy strategies in breast cancer.
  • Analysis of emerging resistance mechanisms in targeted cancer therapy.
  • Focus on EGFR-targeted therapies and associated resistance in TNBC.

Main Results:

  • Targeted therapies have significantly improved outcomes for ER-positive and HER2-positive breast cancer.
  • TNBC presents a significant unmet need for effective targeted treatments.
  • EGFR and combination therapies show promise for TNBC, but resistance is a key challenge.

Conclusions:

  • Targeted therapies are a powerful strategy in breast cancer treatment.
  • Identifying novel targets and combination strategies is critical for TNBC.
  • Further research into overcoming resistance mechanisms is essential for advancing TNBC therapy.
Keywords:
EGFRdrug resistancetarget therapy

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.5K